These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 34547609)

  • 1. Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis.
    Correale J; Halfon MJ; Jack D; Rubstein A; Villa A
    Mult Scler Relat Disord; 2021 Nov; 56():103264. PubMed ID: 34547609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis.
    Kihara Y; Chun J
    Pharmacol Ther; 2023 Jun; 246():108432. PubMed ID: 37149155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailable central nervous system disease-modifying therapies for multiple sclerosis.
    Hartung HP; Cree BAC; Barnett M; Meuth SG; Bar-Or A; Steinman L
    Front Immunol; 2023; 14():1290666. PubMed ID: 38162670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
    Groves A; Kihara Y; Chun J
    J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
    Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
    Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reviewing the Significance of Blood-Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment.
    Balasa R; Barcutean L; Mosora O; Manu D
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovative drug delivery strategies to the CNS for the treatment of multiple sclerosis.
    Mwema A; Muccioli GG; des Rieux A
    J Control Release; 2023 Dec; 364():435-457. PubMed ID: 37926243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis.
    Weier A; Enders M; Kirchner P; Ekici A; Bigaud M; Kapitza C; Wörl J; Kuerten S
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain Barriers and Multiple Sclerosis: Novel Treatment Approaches from a Brain Barriers Perspective.
    Nishihara H; Engelhardt B
    Handb Exp Pharmacol; 2022; 273():295-329. PubMed ID: 33237504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Does the Immune System Enter the Brain?
    Mapunda JA; Tibar H; Regragui W; Engelhardt B
    Front Immunol; 2022; 13():805657. PubMed ID: 35273596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
    Chun J; Hartung HP
    Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does Siponimod Exert Direct Effects in the Central Nervous System?
    Kipp M
    Cells; 2020 Jul; 9(8):. PubMed ID: 32722245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
    Spampinato SF; Obermeier B; Cotleur A; Love A; Takeshita Y; Sano Y; Kanda T; Ransohoff RM
    PLoS One; 2015; 10(7):e0133392. PubMed ID: 26197437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of human glia by multiple sclerosis disease modifying therapies.
    Healy LM; Michell-Robinson MA; Antel JP
    Semin Immunopathol; 2015 Nov; 37(6):639-49. PubMed ID: 26259734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis.
    Schneider R; Oh J
    Curr Neurol Neurosci Rep; 2022 Nov; 22(11):721-734. PubMed ID: 36301434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA; Chun J
    Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis.
    Nishihara H; Shimizu F; Sano Y; Takeshita Y; Maeda T; Abe M; Koga M; Kanda T
    PLoS One; 2015; 10(3):e0121488. PubMed ID: 25774903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The blood-central nervous system barriers actively control immune cell entry into the central nervous system.
    Engelhardt B
    Curr Pharm Des; 2008; 14(16):1555-65. PubMed ID: 18673197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles for lysophospholipid S1P receptors in multiple sclerosis.
    Noguchi K; Chun J
    Crit Rev Biochem Mol Biol; 2011 Feb; 46(1):2-10. PubMed ID: 20979571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.